References
- Zeng SY, Gong Y, Zhang YP, et al. Changes in the prevalence of rheumatic diseases in Shantou, China, in the past three decades: a COPCORD Study. PLoS One 2015;10:e0138492
- Jiménez-Balderas FJ, Mintz G. Ankylosing spondylitis: clinical course in women and men. J Rheumatol 1993;20:2069-72
- Boonen A, van der Linden S M. The burden of ankylosing spondylitis. J Rheumatol 2006;78:4-11
- Ward MM. Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol 2014;33:739-40
- Huscher D, Rudwaleit M, Thiele K, et al. SAT0447 Changes in treatment and outcomes of ankylosing spondylitis in routine care in germany 2000 to 2010. Ann Rheum Dis 2013;71(3 Suppl):623
- Howe A, Eyck LT, Dufour R, et al. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manage Care Pharm 2014;20:1236-44
- van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91
- Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56
- Yang Y, Du F, Ye W, et al. Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis. ClinicoEcon Outcomes Res: CEOR 2015;7:205
- Eggleston K. Health Care for 1.3 Billion: An Overview of China?s Health System (January 9, 2012). Stanford Asia Health Policy Program Working Paper No. 28
- Braun JV, Van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
- Wang XR, Su Y, An Y, et al. [Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China]. J Peking Uni Health Sci 2012;44:182-7
- Kvamme MK, Lie E, Kvien TK, et al. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 2012;51:1618-27
- Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31
- Zeng ZC, Zhao D, Wang WH, et al. The routes of obtaining medical knowledge and resolving clinical issues in Beijing community physicians. Cardio Pulm Vasc Dis J (Chinese) 2004;23:193-5
- Pan YH, Song J. Risk factors affecting treatment compliance in patients with ankylosing spondylitis. Nurs Care J (Chinese) 2012;2:103-4
- Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-5
- Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013;72:1149-55
- Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia‐Pacific Region. Value Health 2008;11(s1):S124-S9